Effects of extended-release niacin with laropiprant in high-risk patients - The New England Journal of Medicine - 2014
Brief Summary:
Among patients with atherosclerotic disease on statin therapy, niacin+laropiprant does not reduce incident major vascular events when compared to placebo. The therapy was poorly tolerated.Reference: http://www.ncbi.nlm.nih.gov/pubmed/25014686
Comments
Post a Comment
Drop your thoughts here, we would love to hear from you